Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 3: Understanding Supersaturation Versus Precipitation Potential During the In Vitro Digestion of Type I, II, IIIA, IIIB and IV Lipid-Based Formulations
- 1.1k Downloads
Recent studies have shown that digestion of lipid-based formulations (LBFs) can stimulate both supersaturation and precipitation. The current study has evaluated the drug, formulation and dose-dependence of the supersaturation – precipitation balance for a range of LBFs.
Type I, II, IIIA/B LBFs containing medium-chain (MC) or long-chain (LC) lipids, and lipid-free Type IV LBF incorporating different doses of fenofibrate or tolfenamic acid were digested in vitro in a simulated intestinal medium. The degree of supersaturation was assessed through comparison of drug concentrations in aqueous digestion phases (APDIGEST) during LBF digestion and the equilibrium drug solubility in the same phases.
Increasing fenofibrate or tolfenamic acid drug loads (i.e., dose) had negligible effects on LC LBF performance during digestion, but promoted drug crystallization (confirmed by XRPD) from MC and Type IV LBF. Drug crystallization was only evident in instances when the calculated maximum supersaturation ratio (SRM) was >3. This threshold SRM value was remarkably consistent across all LBF and was also consistent with previous studies with danazol.
The maximum supersaturation ratio (SRM) provides an indication of the supersaturation ‘pressure’ exerted by formulation digestion and is strongly predictive of the likelihood of drug precipitation in vitro. This may also prove effective in discriminating the in vivo performance of LBFs.
Key wordsbioavailability drug solubilization in vitro digestion testing in vitro models LFCS Consortium lipid-based drug delivery systems precipitation SEDDS solubility supersaturation
Acknowledgments AND DISCLOSURES
This study results from a joint collaboration between members of the LFCS Consortium funded primarily by Capsugel and Sanofi R & D, with additional funding from Gattefossé, Merck Serono, NicOx, Roche, Bristol-Myers Squibb and Actelion. The authors would like to thank Dr. Laura Gordon and the Chemical Engineering department at Melbourne University for the XRPD analysis, and Rhiannon Smythe and Samuel Wood for determining the fenofibrate solubilities in the digested lipid formulations.
- 3.Hauss DJ. Enhancing the bioavailability of poorly water-soluble drugs. New York: Informa Healthcare; 2007.Google Scholar
- 14.Anby MU, Williams HD, McIntosh M, Benameur H, Edwards GA, Pouton CW, et al. Lipid digestion as a trigger for supersaturation: in vitro and in vivo evaluation of the utility of polymeric precipitation inhibitors in self emulsifying drug delivery systems. Mol Pharm. 2012;9:2063–79.CrossRefGoogle Scholar
- 18.Yeap YY, Trevaskis NL, Quach T, Tso P, Charman WN, and Porter CJH. Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation. Mol Pharmaceut. 2013. doi: 10.1021/mp3006566
- 19.Yeap YY, Trevaskis NL, and Porter CJH. The acidic microclimate of the intestinal unstirred water layer can promote drug absorption from long-chain mixed micelles via induction of supersaturation at the absorptive site. Pharm Res. This issue:2013.Google Scholar
- 20.Williams HD, Anby MU, Sassene P, Kleberg K, Bakala N’Goma JC, Calderone M, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations: 2) The effect of bile salt concentration and drug loading on the performance of Type I, II, IIIA, IIIB and IV formulations during in vitro digestion. Mol Pharm. 2012;9:3286–300.PubMedCrossRefGoogle Scholar
- 25.Williams HD, Sassene P, Kleberg K, Bakala N’Goma JC, Calderone M, Jannin V, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations: 1) Method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. J Pharm Sci. 2012;101:3360–80.PubMedCrossRefGoogle Scholar
- 26.Sassene P, Kleberg K, Williams HD, Bakala N’Goma JC, Calderone M, Jannin V, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations: 3) Effect of calcium and pancreatin concentration. In preparation 2013.Google Scholar
- 35.Anderson KV, Larsen S, Alhede B, Gelting N, Buchardt O. Characterization of two polymorphic forms of tolfenamic acid, N-(2-Methyl-3-chlorophenyl)anthranilic acid: their crystal structures and relative stabilities. J Chem Soc Perkin Trans. 1989;2:1443–7.Google Scholar
- 42.Kossena GA, Boyd BJ, Porter CJH, Charman WN. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. J Pharm Sci. 2003;92:634–48.PubMedCrossRefGoogle Scholar
- 44.Porter CJH, Kaukonen AM, Taillardat-Bertschinger A, Boyd BJ, O’Connor JM, Edwards GA, et al. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. J Pharm Sci. 2004;93:1110–21.PubMedCrossRefGoogle Scholar
- 47.Devraj R, Williams HD, Warren DB, Porter CJH, and Pouton CW. Effect of different nonionic surfactants in self-emulsifying lipid formulations on supersaturation during in vitro digestion. Submitted, 2013.Google Scholar
- 48.Williams HD, Pouton CW, and Porter CJH. Lipid-based formulations and drug supersaturation: Harnessing the unique benefits of the lipid digestion/absorption pathway. Pharm Res. This issue:2013.Google Scholar
- 49.Bevernage J, Brouwers J, Annaert P, Augustijns P. Drug precipitation-permeation interplay: supersaturation in an absorptive environment. Eur J Pharm Biopharm. 2012;82:424–8.Google Scholar
- 50.Bevernage J, Brouwers J, Brewster ME, and Augustijns P. Evaluation of gastrointestinal drug supersaturation and precipitation: Strategies and issues. Int J Pharm. 2012. doi: 10.1016/j.ijpharm.2012.11.026
- 53.Kashchiev D, von Rosmalen GM. Review: nucleation in solutions revisited. Cryst Res Technol. 2003;38:555–74.Google Scholar
- 54.Williams HD, Hergaden B, and Porter CJH. Drug supersaturation in digested lipid-based drug delivery systems. AAPS J. S2:2012.Google Scholar